PT  - JOURNAL ARTICLE
AU  - MUSTAPHA M. BOUHENNA
AU  - BARBORA ORLIKOVA
AU  - OUALID TALHI
AU  - BEN SCHRAM
AU  - DIANA C.G.A. PINTO
AU  - NADIA TAIBI
AU  - KHALDOUN BACHARI
AU  - MARC DIEDERICH
AU  - ARTUR M.S. SILVA
AU  - NABIL MAMERI
TI  - Anti-proliferative, Cytotoxic and NF-ĸB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia
DP  - 2017 Sep 01
TA  - Anticancer Research
PG  - 5225--5233
VI  - 37
IP  - 9
4099  - http://ar.iiarjournals.org/content/37/9/5225.short
4100  - http://ar.iiarjournals.org/content/37/9/5225.full
SO  - Anticancer Res2017 Sep 01; 37
AB  - Background/Aim: NF-ĸB affects most aspects of cellular physiology. Deregulation of NF-ĸB signaling is associated with inflammatory diseases and cancer. In this study, we evaluated the cytotoxic and NF-ĸB inhibition potential of new spiro(lactone-cyclohexanone) compounds in two different human leukemia cell lines (U937 and K562). Materials and Methods: The anti-proliferative effects of the spiro(lactone-cyclohexanone) compounds on human K562 and U937 cell lines was evaluated by trypan blue staining, as well as their involvement in NF-kB regulation were analyzed by luciferase reporter gene assay, Caspase-3/7 activities were evaluated to analyze apoptosis induction. Results: Both spiro(coumarin-cyclohexanone) 4 and spiro(6- methyllactone-cyclohexanone) 9 down-regulated cancer cell viability and proliferation. Compound 4 inhibited TNF-α-induced NF-ĸB activation in a dose-dependent manner and induced caspase-dependent apoptosis in both leukemia cell lines. Conclusion: Results show that compound 4 and compound 9 have potential as anti-cancer agents. In addition, compound 4 exerted NF-kB inhibition activity in leukemia cancer cells.